Does palliative chemotherapy beyond three courses benefit patients with non-small-cell lung cancer?: Commentary

Nature Clinical Practice Oncology

Volumn 4, Issue 5, 2007, Pages 274-275

  Gridelli, Cesare ^a  

^a S G MOSCATI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; IFOSFAMIDE; MITOMYCIN C; NAVELBINE; PLATINUM COMPLEX;

CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE CALCULATION; DYSPNEA; FATIGUE; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCANDINAVIA; SHORT SURVEY; SURVIVAL RATE; SURVIVAL TIME;

EID: 34248553601     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0776     Document Type: Short Survey

References (4)

1. Smith IE et al. (2001) Duration of chemotherapy in advanced non small cell lung cancer: A randomised trial of three versus six courses of mitomycin C, vinblastine, and cisplatin. J Clin Oncol 19: 1336-1343
2. Socinski MA et al. (2002) Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20: 1335-1343
3. Weestel V et al. (2005) Randomised study of maintenance vinorelbine in responders with advanced non small cell lung cancer. J Natl Cancer Inst 97: 499-506
4. Brodowicz T et al. (2006) Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non small cell lung cancer: A phase III trial. Lung Cancer 52: 155-163